FGFR2 and cholangiocarcinoma: Considering these findings, a randomized controlled phase III study (FIGHT-302) is currently underway to assess and compare the effectiveness and safety of first line pemigatinib in contrast to gemcitabine plus cisplatin in the management of patients diagnosed with advanced CCA exhibiting FGFR2 rearrangements [111].